headache-1540220

Improving financial flexibility

PDL BioPharma 4 March 2016 Update

PDL BioPharma

Improving financial flexibility

Dividend update

Pharma & biotech

4 March 2016

Price

US$3.42

Market cap

US$562m

Net debt ($m) at end Q415

38.9

Shares in issue

164.3m

Free float

92%

Code

PDLI

Primary exchange

NASDAQ

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

22.1

(5.0)

(51.3)

Rel (local)

17.2

(2.3)

(48.5)

52-week high/low

US$7.3

US$2.8

Business description

PDL BioPharma has reinvented itself through a two-pronged strategy of investing in royalty streams of marketed and development-stage therapeutics, and providing high-yield debt financing to medical device and diagnostic companies with near-term product launches.

Next events

Earnings

Q116

Analysts

Maxim Jacobs

+1 646 653 7027

Dr Nathaniel Calloway

+1 646 653 7036

PDL BioPharma is a research client of Edison Investment Research Limited

As the Queen royalty streams approach expiry, PDL has taken steps to preserve its cash flow by announcing a dividend cut for Q1 to $0.05 per share (from $0.15 per share), which would save the company more than $65m on an annualized basis. This allows PDL BioPharma to meet its financial obligations and gives it greater financial flexibility to make either more deals, larger deals or both, as current market conditions are favorable to alternative financing.

Year end

Revenue ($m)

PBT*
($m)

EPS*
($)

DPS
($)

P/E
(x)

Yield
(%)

12/14

581.2

501.3

2.04

0.61

1.7

17.8

12/15

590.4

530.1

2.04

0.59

1.7

17.3

12/16e

206.5

149.4

0.58

0.20

5.9

5.8

12/17e

73.8

13.7

0.05

0.20

68.4

5.8

Note: *PBT and EPS are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments.

Dividend reduction markedly improves free cash flow

The reduction of PDL’s quarterly dividend by 67% to $0.05 allows the company to maintain a respectable yield of 6.8% while providing potentially increased cash flow per year if the rate is maintained. The move is not wholly unexpected, as cash flow and profitability will be lower going forward due to the expiration of the Queen et al patents in Q116. Historically, the royalties associated with those patents have provided approximately $120m per quarter.

Biotech burst creates market for alternative deals

The current turmoil in the equity and bond markets creates an ideal environment for alternative financing and the type of royalty-backed transactions that PDL offers. The increase in cash flow from the dividend cut will allow the company to take advantage of these conditions while equity and bond markets remain depressed.

Solid quarter: 12% increase in non-Queen revenue

PDL reported Q415 and full year results, showing a 12% increase in revenue for the year from non-Queen sources. The increase was largely driven by increases in royalties from Glumetza and a corresponding increase in fair value following resolution of payment issues from partner Valeant. The company generated $333m in earnings for the year (4% increase) with an ending cash and equivalents of $219m.

Valuation: Slight adjustment to $1033m

We are slightly decreasing our valuation to $1,033m from $1,034m, corresponding to a reduction to $6.29 per basic and diluted share compared $6.30 per share in Q315. A decrease in net debt over the period was balanced by the effect of the near term expiration of the queen patents and other effects associated with rolling over our NPVs to 2016.

Dividend reduction

This dividend reduction, although large on a relative scale, still allows the company to preserve a respectable yield of 6.8%, while providing cash flow to support its immediate obligations through early 2018, as well as investment in future royalty streams. This will provide the company with an additional $16.4m per quarter in cash if the rate is maintained. We previously projected a cash shortfall of $77m by the end of 2018, so the new dividend should be more than sufficient to meet its obligations and provide liquidity for new transactions.

Ability to service obligations secure through early 2018

The reduction in the dividend was essential to meet a series of obligations, the largest of which is the company’s $246m in outstanding convertible debt, due in February 2018. The company was also scheduled to pay $25m to complete repayment of its term loan from RBC in Q116. Outside debt, the company is committed to providing $50m in financing to Ariad and potentially $20m to CareView if it can meet certain milestone conditions. As a reminder, the Ariad deal provided an initial $50m in financing in July 2015, with the obligation for PDI to provide an additional $50m one year later. Additionally, Ariad has the option to request $100m in additional financing during the six months before the final payment. Collectively, PDL’s obligations are associated with $433m ($533m with the Ariad option) in payments by Q118 (Exhibit 1).

Exhibit 1: PDL obligations

Obligation

Time frame

Cost ($m)

Dividends

2016-17

68

RBC term loan

Q116

25

Ariad payment

Q216

50

CareView payment (assuming milestones and other conditions met)

Q217

20

Interest on convertible debt

2016-17

24

Outstanding convertible debt

Q118

246

Total

433

Source: Company filings

Although the majority of positive cash flows are associated with the Queen patents and will be ending in Q116, many note agreements are scheduled to begin principal repayment in the next two years (Exhibit 2). The principal payments and existing licensing revenue should provide sufficient capital to service the debt and other obligations with the new dividend structure. However, PDL may seek short-term financing in the future, enabling it to do more deals or to finance the Ariad option.

Exhibit 2: Principal payment schedule

Beginning

Ending

Payment per
quarter ($m)

Total principal
($m)

LENSAR

3/31/18

12/15/20

5.25

42

Direct Flow

9/30/16

11/5/18

5

50

Paradigm Spine

12/31/16

2/14/19

5

50

Total

142

Source: Company filings

Tough healthcare market may be a boon for PDL

Like many other companies, PDL has been a victim of the downturn in biotech, but it is in a unique position to profit from the situation as the need for alternative financing increases. For instance, Halozyme recently entered into a $150m debt agreement backed by royalties for its Enhanze technology. The last financial downturn in 2008 was also characterized by an increase in healthcare royalty deals and the founding of a number of funds associated with royalty-backed instruments.1

Drug royalty financing thrives in difficult market (2008), Reuters.

However, worsening financial market conditions could increase the rate of corporate defaults if clients are unable to obtain other financing to maintain operations and service their debt or royalty agreements to PDL. There is relatively little risk of interruption of revenue streams from royalty contracts, as they are by and large with well-established companies, but the debt agreements do pose a potential risk. Having said that, recent experience with LENSAR has shown that even these issues can be resolved in a manner favorable to PDL.

Quarterly update

PDL recently presented their Q415 and year-end earnings reporting a revenue of $178m for the quarter and $590m for the year. This revenue exceeded our expectations (by $32m) due to a larger than expected royalty revenue of $34m outside of the Queen, et al., patents. The company explained on the earnings call that this was predominantly from the Glumetza royalty stream. There was previously a degree of uncertainty surrounding the royalty considering difficulties receiving payment from Valeant (see our update note published on 18 November 2015). Glumetza and the associated royalty agreement were acquired by Valeant during its acquisition of Salix, which had been stuffing channels with the drug. More recently, Valeant failed to report any revenue for the purposes of royalty calculation to PDL for Q315 filings due to inventory backlogs and late payments. PDL recently initiated royalty auditing proceedings, as the true sales of the drug remain somewhat unclear. The problem seems to be resolving because the company reported $18.9m in payments for Q315 sales and increasing royalty payments over Q415 ($5.3 million, $7.7 million, and $13.1 million for October, November, and December, respectively; December payments to be recognized in Q116). There will likely be some erosion of Glumetza sales over the coming year because of three generics entering the market (one launched in February, the remainder in Q3), but the runway for the royalty stream extends to 2023, and approximately 67% of the principal of the deal has been recovered since signing in 2013. Altogether, non-Queen revenue increased from $94m to $105m between 2014 and 2015 (12% increase).

The royalty payments for Queen, et al., patents was $121m for the quarter and $485m for the year. The Queen royalties are booked on a one quarter lag. Royalties from products sold by Genentech and Roche ended in December 2015, and therefore, the largest remaining portion of the payments will appear on Q116 reports. However, there might be some tail to the revenues because the remaining agreements cover products manufactured before patent expiration in December 2014, and some of these inventories may remain.

In news relating to PDL’s other investments, last October Sanofi issued a voluntary recall of its Auvi-Q epinephrine autoinjector devices due to inaccuracies in the quantity of drug delivered. Auvi-Q was licensed by Kaleo Inc., who has a $145m outstanding note due to PDL. It was announced on the PDL Q415 earnings call that Sanofi has returned the rights of the Auvi-Q injector to Kaleo. Although these developments put the future of Auvi-Q in question, this does not necessarily mean Kaleo will struggle with their loan repayments. First, the terms of the loan stipulated that Kaleo maintain a $20m reserve account to satisfy interest payments in the event of a shortfall, and PDL reported that this account alone should be sufficient to satisfy interest obligations through Q216. Also, Kaleo has an established commercial operation and sells the Evzio naloxone autoinjector in the US. They will not necessarily need to find another partner to relaunch Auvi-Q. This being said, it is unclear at this time the severity of the issues that lead to the recall or how long Auvi-Q will be off the market, although they intend to continue making payments through the interim.

Operational expenses for the year increased $5m and were largely due to legal costs associated with the LENSAR restructuring and the expenses associated with Wellstat Diagnostics. The company has initiated liquidation proceedings with regard to the assets secured against the Wellstat notes and reiterated its stance that the value of the assets exceeds the note principle. Wellstat sold a priority review voucher to AstraZeneca in September 2015 for an undisclosed amount, but previous priority review vouchers have fetched prices in the hundreds of millions, with the most recent public deal between United Therapeutics and AbbVie valued at $350m. PDL has filed for summary judgements in New York against Wellstat’s voucher and other assets. The company records a book value for the Wellstat notes of $50.2m, but the exact terms of the loan have not been made public.

Valuation

We are slightly decreasing our valuation to $1,033m from $1,034m, corresponding to a reduction to $6.29 per basic share ($6.28 per diluted share) compared to $6.30 per basic share ($6.27 per diluted share) in Q315. Different effects balanced in our model such that the valuation did significantly change. Net debt decreased from $101.7 to $38.9 over the quarter (due to planned drawdowns on the term loan and an increase in convertible note buybacks), but this effect was offset by changes in our calculated NPVs as we roll over our valuation to 2016. The change in NPVs was dominated by the reduction in value for the Queen, et al patents as they approach extinguishment in early 2016. It is worth noting that the current EV of the company ($523m) is less than the book value of PDL’s assets from Q415 filings ($766m), a discount of 32%.

Exhibit 3: PDL valuation

Royalty/Note

Type

Expiration year

PDL balance sheet
carrying value

NPV

Queen et al

Royalty

2015

N/A

$80.2

Depomed

Royalty on Glumetza and other products

2024

$191.9

$223.5

VB

Royalty on Spine Implant

Undisclosed

$17.1

$24.5

University of Michigan

Royalty on Cerdelga

2022

$70.2

$35.5

Lilly

Royalty on solanezumab

2030

N/A

$161.4

DirectFlow

Note

2018

$53.9

$49.2

Wellstat

Note (Impaired)

Unknown

$50.2

$50.2

Hyperion

Note (Impaired)

Unknown

$1.2

$1.2

Avinger

Royalty

2018

$2.5

$3.7

Lensar

Note

2018

$42.3

$56.8

Paradigm Spine

Note

2019

$54.0

$55.2

Kaleo

Note

2029

$146.8

$154.8

Acelrx

Royalty on Zalviso

2027

$67.4

$67.5

Ariad

Royalty on Iclusig

2033

$50.0

$87.1

Careview

Note

2022

$18.6

$20.7

Total

 

 

 

$1,072

Net Debt (Q415) ($m)

($38.9)

Total firm value ($m)

$1,033

Total basic shares (m)

164.3

Value per basic share ($)

$6.29

Total options

0.2

Total number of shares

164.5

Diluted value per share ($)

$6.28

Source: Edison Investment Research, company reports

Financials

Revenue for Q415 exceeded our expectations at $590m compared to our estimate of $558m. The difference between the values is largely due to a difference in the change in fair value of royalty rights. We are currently maintaining our forecasts. PDL ended Q415 with $219 in cash, compared to the $227.5 reported in Q315. This was lower than our previous estimates of $243m primarily due to an increase in cash used to repurchase convertible notes. We are currently modelling a stable $0.05 quarterly dividend though 2018. Under these conditions, PDL will not need to refinance existing debt, but may seek short-term financing to take advantage of the favorable market or to fund the $100m Ariad option before the increase in cash flows associated with principle repayments in 2017 onwards. Additionally, if Kaleo is unable to successfully relaunch Auvi-Q, its $145m loan agreement with the company may be at risk.

Exhibit 4: Financial summary

2014

2015

2016e

2017e

Year end 31 December

US GAAP

US GAAP

US GAAP

US GAAP

PROFIT & LOSS

Revenue

 

 

581,225

590,448

206,501

73,800

Cost of Sales

0

0

0

0

Gross Profit

581,225

590,448

206,501

73,800

General & Administrative

(34,914)

(36,090)

(38,977)

(42,095)

EBITDA

 

 

546,311

550,379

167,524

31,705

Operating Profit (before GW and except.)

 

546,311

550,379

167,524

31,705

Intangible Amortisation

0

0

0

0

Other

0

(3,979)

0

0

Exceptionals

0

0

0

0

Operating Profit

546,311

550,379

167,524

31,705

Net Interest

(38,896)

(26,691)

(18,080)

(18,040)

Other

(6,143)

6,450

0

0

Profit Before Tax (norm)

 

 

501,272

530,138

149,444

13,665

Profit Before Tax (FRS 3)

 

 

501,272

530,138

149,444

13,665

Tax

(179,028)

(197,343)

(52,305)

(4,783)

Deferred tax

(0)

(0)

(0)

(0)

Profit After Tax (norm)

322,244

332,795

97,138

8,882

Profit After Tax (FRS 3)

322,244

332,795

97,138

8,882

Average Number of Shares Outstanding (m)

158.2

163.4

166.7

170.0

EPS - normalised (c)

 

 

203.66

203.69

58.29

5.23

EPS - FRS 3 (c)

 

 

2.04

2.04

0.58

0.05

Dividend per share (c)

61.1

60.2

20.0

20.0

Gross Margin (%)

100.0

100.0

100.0

100.0

EBITDA Margin (%)

94.0

93.2

81.1

43.0

Operating Margin (before GW and except.) (%)

94.0

93.2

81.1

43.0

BALANCE SHEET

Fixed Assets

 

 

606,453

733,468

653,143

594,784

Intangible Assets

0

0

0

0

Tangible Assets

62

31

61

91

Royalty rights

259,244

399,204

407,337

370,733

Other

347,147

334,233

245,746

223,959

Current Assets

 

 

355,897

279,731

351,298

436,601

Stocks

0

0

0

0

Debtors

300

0

0

0

Cash

291,377

218,883

287,829

377,632

Other

64,220

60,848

63,469

58,969

Current Liabilities

 

 

(187,983)

(36,662)

(11,696)

(249,211)

Creditors

(318)

(394)

(394)

(394)

Short term borrowings

(175,496)

(24,966)

0

(237,515)

Other

(12,169)

(11,302)

(11,302)

(11,302)

Long Term Liabilities

 

 

(313,930)

(283,485)

(285,813)

(50,650)

Long term borrowings

(276,228)

(232,835)

(235,163)

0

Other long term liabilities

(37,702)

(50,650)

(50,650)

(50,650)

Net Assets

 

 

460,437

693,052

706,932

731,524

CASH FLOW

Operating Cash Flow

 

 

292,281

301,465

71,572

(11,377)

Net Interest

0

0

0

0

Tax

0

0

0

0

Capex

(49)

(9)

(30)

(30)

Acquisitions/disposals

21,360

(71,593)

33,735

73,207

Financing

0

0

0

0

Dividends

(96,557)

(98,307)

(33,331)

(33,997)

Other

(159,420)

(8,046)

22,000

62,000

Net Cash Flow

57,615

123,510

93,946

89,803

Opening net debt/(cash)

 

 

300,978

160,347

38,918

(52,666)

HP finance leases initiated

0

0

0

0

Exchange rate movements

0

0

0

0

Other

83,016

(2,081)

(2,362)

(2,352)

Closing net debt/(cash)

 

 

160,347

38,918

(52,666)

(140,117)

Source: Edison Investment Research, company reports

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by PDL BioPharma and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Share this with friends and colleagues